Page 51 - 《中国药科大学学报》2026年第1期

第 57 卷第 1 期 邴天德，等：乳酸脱氢酶 A 抑制剂的设计、合成与生物活性 45

优的成药性。最后，对化合物 25 进行了体外细胞毒 substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of
human lactate dehydrogenase[J]. Bioorg Med Chem Lett, 2013,
性评价，其在胰腺癌细胞中显示出微摩尔级的抑制
23(11): 3186-3194.
活性（IC = 28.09 μmol/L），在正常细胞中显示出优 [13] Zhou Y, Tao PD, Wang MG, et al. Development of novel hu-
50
良的安全性。本研究为后续开发兼具优良成药性和 man lactate dehydrogenase A inhibitors: high-throughput
强效抑制活性的 LDHA 抑制剂奠定了实验基础。 screening, synthesis, and biological evaluations[J]. Eur J Med
Chem, 2019, 177: 105-115.
[14] Cox JH, Boily MO, Caron A, et al. Characterization of CHK-
336, a first-in-class, liver-targeted, small-molecule lactate dehy-
References
drogenase inhibitor for hyperoxaluria treatment[J]. J Am Soc
[1] Valvona CJ, Fillmore HL, Nunn PB, et al. The regulation and Nephrol, 2025, 36(8): 1535-1547.
function of lactate dehydrogenase A: therapeutic potential in [15] Lobo S. Is there enough focus on lipophilicity in drug discov-
brain tumor[J]. Brain Pathol, 2016, 26(1): 3-17. ery[J]? Expert Opin Drug Discov, 2020, 15(3): 261-263.
[2] Bai Y, Guo XY, Qin QL, et al. Advances in research on mecha- [16] Syed YY. Nedosiran: first approval[J]. Drugs, 2023, 83(18):
nism of lactate dehydrogenase B in tumors[J]. J China Pharm 1729-1733.
Univ (中国药科大学学报), 2023, 54(2): 172-179. [17] Ariceta G, Barrios K, Brown BD, et al. Hepatic lactate dehydro-
[3] Rai G, Urban DJ, Mott BT, et al. Pyrazole-based lactate dehy- genase A: an RNA interference target for the treatment of all
drogenase inhibitors with optimized cell activity and pharma- known types of primary hyperoxaluria[J]. Kidney Int Rep, 2021,
cokinetic properties[J]. J Med Chem, 2020, 63(19): 10984- 6(4): 1088-1098.
11011. [18] Zhang MM, Bahal R, Rasmussen TP, et al. The growth of siR-
[4] Krisher RL, Prather RS. A role for the Warburg effect in preim- NA-based therapeutics: updated clinical studies[J]. Biochem
plantation embryo development: metabolic modification to sup- Pharmacol, 2021, 189: 114432.
port rapid cell proliferation[J]. Mol Reprod Dev, 2012, 79(5): [19] Gong QJ, Song J, Song YH, et al. New techniques and strate-
311-320. gies in drug discovery (2020-2024 update)[J]. Chin Chem Lett,
[5] Vander Heiden MG. Exploiting tumor metabolism: challenges 2025, 36(3): 110456.
for clinical translation[J]. J Clin Invest, 2013, 123(9): 3648- [20] Abraham MJ, Murtola T, Schulz R, et al. GROMACS: High
3651. performance molecular simulations through multi-level paral-
[6] Martin-Higueras C, Torres A, Salido E. Molecular therapy of lelism from laptops to supercomputers[J]. SoftwareX, 2015, 1:
primary hyperoxaluria[J]. J Inherit MeTable Dis, 2017, 40(4): 19-25.
481-489. [21] Gong QJ, Dong Y, Liang JQ, et al. Machine-learning-driven
[7] Lai CJ, Pursell N, Gierut J, et al. Specific inhibition of hepatic discovery of N-phenylbenzenesulfonamides as a novel chemo-
lactate dehydrogenase reduces oxalate production in mouse type for lactate dehydrogenase A inhibition with anti-pancreatic
models of primary hyperoxaluria[J]. Mol Ther, 2018, 26(8): cancer activity[J]. J Med Chem, 2025, 68(14): 14384-14404.
1983-1995. [22] Bakchi B, Krishna AD, Sreecharan E, et al. An overview on ap-
[8] Van Wilpe S, Koornstra R, Den Brok, M, et al. Lactate dehy- plications of SwissADME web tool in the design and develop-
drogenase: a marker of diminished antitumor immunity[J]. On- ment of anticancer, antitubercular and antimicrobial agents: a
coimmunology, 2020, 9(1): 1731942. medicinal chemist’s perspective[J]. J Mol Struct, 2022, 1259:
[9] Rellinger EJ, Craig BT, Alvarez AL, et al. FX11 inhibits aero- 132712.
bic glycolysis and growth of neuroblastoma cells[J]. Surgery, [23] Unsal V, Yildiz R, Korkmaz A, et al. Evaluation of extra virgin
2017, 161(3): 747-752. olive oil compounds using computational methods: in vitro,
[10] Billiard J, Dennison JB, Briand J, et al. Quinoline 3-sulfon- ADMET DFT molecular docking and human gene network
amides inhibit lactate dehydrogenase A and reverse aerobic gly- analysis study[J]. BMC Chem, 2025, 19(1): 3.
colysis in cancer cells[J]. Cancer Metab, 2013, 1(1): 19. [24] Phan TQ, Wang SL, Le Vu TT, et al. Inside into diverse phar-
[11] Boudreau A, Purkey HE, Hitz A, et al. Metabolic plasticity un- maceutical properties and phytochemical profiles of tetrastigma
derpins innate and acquired resistance to LDHA inhibition[J]. erubescens: a drug discovery via experiments, docking, DFT,
Nat Chem Biol, 2016, 12(10): 779-786. ADMET and Lipinski’s rules of five performance[J]. Res Chem
[12] Dragovich PS, Fauber BP, Corson LB, et al. Identification of Intermed, 2025, 51(6): 3351-3381.